» Articles » PMID: 35355296

Comparison of Model-specific Histopathology in Mouse Models of COVID-19

Overview
Journal J Med Virol
Specialty Microbiology
Date 2022 Mar 31
PMID 35355296
Authors
Affiliations
Soon will be listed here.
Abstract

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified as the causative agent of the current coronavirus disease 2019 pandemic. Development of animal models that parallel the clinical and pathologic features of disease are highly essential to understanding the pathogenesis of SARS-CoV-2 infection and the development of therapeutics and prophylactics. Several mouse models that express the human angiotensin converting enzyme 2 (hACE2) have been created, including transgenic and knock-in strains, and viral vector-mediated delivery of hACE2. However, the comparative pathology of these mouse models infected with SARS-CoV-2 are unknown. Here, we perform systematic comparisons of the mouse models including K18-hACE2 mice, KI-hACE2 mice, Ad5-hACE2 mice and CAG-hACE2 mice, which revealed differences in the distribution of lesions and the characteristics of pneumonia induced. Based on these observations, the hACE2 mouse models meet different needs of SARS-CoV-2 researches. The similarities or differences among the model-specific pathologies may help in better understanding the pathogenic process of SARS-CoV-2 infection and aiding in the development of effective medications and prophylactic treatments for SARS-CoV-2.

Citing Articles

Rapid Development of Small Rodent Animal Models for Infectious Disease Research Through Vectorized Receptor Molecule Expression.

Goens M, Howard E, Warner B, Susta L, Wootton S Viruses. 2024; 16(11).

PMID: 39599908 PMC: 11599079. DOI: 10.3390/v16111794.


Innate immunity and interferon in SARS-CoV-2 infection outcome.

Savan R, Gale Jr M Immunity. 2023; 56(7):1443-1450.

PMID: 37437537 PMC: 10361255. DOI: 10.1016/j.immuni.2023.06.018.


Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies.

Liu M, Gan H, Liang Z, Liu L, Liu Q, Mai Y Front Microbiol. 2023; 14:1122868.

PMID: 37007494 PMC: 10060843. DOI: 10.3389/fmicb.2023.1122868.


Early pathogenesis profiles across SARS-CoV-2 variants in K18-hACE2 mice revealed differential triggers of lung damages.

Aw Z, Mok C, Wong Y, Chen H, Mak T, Lin R Front Immunol. 2022; 13:950666.

PMID: 36389747 PMC: 9648130. DOI: 10.3389/fimmu.2022.950666.


Characteristics of animal models for COVID-19.

Qi F, Qin C Animal Model Exp Med. 2022; 5(5):401-409.

PMID: 36301011 PMC: 9610135. DOI: 10.1002/ame2.12278.


References
1.
Yao X, Luo T, Shi Y, He Z, Tang R, Zhang P . A cohort autopsy study defines COVID-19 systemic pathogenesis. Cell Res. 2021; 31(8):836-846. PMC: 8208380. DOI: 10.1038/s41422-021-00523-8. View

2.
West M, Roman A, Sayan E, Primrose J, Wedge S, Underwood T . A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer. Crit Rev Oncol Hematol. 2017; 112:80-102. DOI: 10.1016/j.critrevonc.2017.02.008. View

3.
Hariri L, North C, Shih A, Israel R, Maley J, Villalba J . Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review. Chest. 2020; 159(1):73-84. PMC: 7538870. DOI: 10.1016/j.chest.2020.09.259. View

4.
Sun S, Chen Q, Gu H, Yang G, Wang Y, Huang X . A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe. 2020; 28(1):124-133.e4. PMC: 7250783. DOI: 10.1016/j.chom.2020.05.020. View

5.
Oladunni F, Park J, Pino P, Gonzalez O, Akhter A, Allue-Guardia A . Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020; 11(1):6122. PMC: 7705712. DOI: 10.1038/s41467-020-19891-7. View